Brian Abrahams
Stock Analyst at RBC Capital
(3.27)
# 1,105
Out of 4,667 analysts
425
Total ratings
44.04%
Success rate
2.85%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Upgrades: Sector Perform | $4 | $4.91 | -18.53% | 21 | Nov 21, 2024 | |
| INCY Incyte | Maintains: Sector Perform | $80 → $74 | $70.55 | +4.89% | 19 | Nov 19, 2024 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $81 → $84 | $88.63 | -5.22% | 28 | Nov 18, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Outperform | $50 → $48 | $2.72 | +1,664.71% | 10 | Nov 15, 2024 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $32 → $31 | $13.65 | +127.11% | 3 | Nov 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $437 → $451 | $447.41 | +0.80% | 48 | Nov 5, 2024 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $10 | $7.30 | +36.99% | 15 | Nov 5, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,260 → $1,215 | $743.35 | +63.45% | 30 | Nov 1, 2024 | |
| GLPG Galapagos NV | Maintains: Sector Perform | $32 → $30 | $25.64 | +17.00% | 11 | Nov 1, 2024 | |
| MRNS Marinus Pharmaceuticals | Maintains: Sector Perform | $3 → $1 | $0.31 | +223.62% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $182 | $109.40 | +66.36% | 31 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $9.77 | +104.81% | 14 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $133 | $123.29 | +7.88% | 16 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $34 | $41.96 | -18.97% | 17 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $108 | $85.64 | +26.11% | 18 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $292 → $269 | $156.00 | +72.44% | 33 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $82 | $16.08 | +409.95% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $9.79 | +196.22% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $39.34 | +39.81% | 13 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $24 | $14.40 | +66.67% | 9 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3 | $0.78 | +287.10% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $7.98 | +50.38% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $9.43 | +27.25% | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.52 | +192.55% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $45 | $12.73 | +253.50% | 11 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $9.08 | +65.20% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.59 | +466.04% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $42.93 | -23.13% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $46.40 | - | 4 | Dec 4, 2017 |
Sage Therapeutics
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $4.91
Upside: -18.53%
Incyte
Nov 19, 2024
Maintains: Sector Perform
Price Target: $80 → $74
Current: $70.55
Upside: +4.89%
Gilead Sciences
Nov 18, 2024
Maintains: Sector Perform
Price Target: $81 → $84
Current: $88.63
Upside: -5.22%
HOOKIPA Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $50 → $48
Current: $2.72
Upside: +1,664.71%
Contineum Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $31
Current: $13.65
Upside: +127.11%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Sector Perform
Price Target: $437 → $451
Current: $447.41
Upside: +0.80%
BioCryst Pharmaceuticals
Nov 5, 2024
Reiterates: Outperform
Price Target: $10
Current: $7.30
Upside: +36.99%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,260 → $1,215
Current: $743.35
Upside: +63.45%
Galapagos NV
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $25.64
Upside: +17.00%
Marinus Pharmaceuticals
Oct 25, 2024
Maintains: Sector Perform
Price Target: $3 → $1
Current: $0.31
Upside: +223.62%
Oct 21, 2024
Reiterates: Outperform
Price Target: $182
Current: $109.40
Upside: +66.36%
Oct 18, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $9.77
Upside: +104.81%
Oct 8, 2024
Reiterates: Sector Perform
Price Target: $133
Current: $123.29
Upside: +7.88%
Oct 4, 2024
Maintains: Sector Perform
Price Target: $32 → $34
Current: $41.96
Upside: -18.97%
Oct 4, 2024
Maintains: Outperform
Price Target: $106 → $108
Current: $85.64
Upside: +26.11%
Oct 4, 2024
Maintains: Outperform
Price Target: $292 → $269
Current: $156.00
Upside: +72.44%
Sep 20, 2024
Reiterates: Outperform
Price Target: $82
Current: $16.08
Upside: +409.95%
Sep 4, 2024
Reiterates: Outperform
Price Target: $29
Current: $9.79
Upside: +196.22%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $39.34
Upside: +39.81%
Aug 9, 2024
Maintains: Sector Perform
Price Target: $28 → $24
Current: $14.40
Upside: +66.67%
Aug 7, 2024
Reiterates: Outperform
Price Target: $3
Current: $0.78
Upside: +287.10%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $7.98
Upside: +50.38%
Jul 17, 2024
Reiterates: Outperform
Price Target: $12
Current: $9.43
Upside: +27.25%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $7.52
Upside: +192.55%
May 7, 2024
Maintains: Outperform
Price Target: $54 → $45
Current: $12.73
Upside: +253.50%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $9.08
Upside: +65.20%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.59
Upside: +466.04%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $42.93
Upside: -23.13%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $46.40
Upside: -